Skip to main content

Common Variable Immunodeficiency

3
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CSL Seqirus
CSL SeqirusUK - Maidenhead
3 programs
1
1
VivaglobinPhase 4
Human Normal Immunoglobulin for Subcutaneous AdministrationPhase 3
gammaglobulinN/A
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
STA-5326Phase 11 trial
Active Trials
NCT00263237Completed10Est. Jul 2008
CSL Behring
CSL BehringIL - Bradley
3 programs
gammaglobulinN/A1 trial
Human Normal Immunoglobulin for Subcutaneous AdministrationPHASE_31 trial
VivaglobinPHASE_41 trial
Active Trials
NCT00661401Completed5Est. Nov 2002
NCT00542997Completed51Est. Aug 2009
NCT00520494Completed18Est. Oct 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
CSL BehringVivaglobin
CSL BehringHuman Normal Immunoglobulin for Subcutaneous Administration
Allergy TherapeuticsSTA-5326
CSL Behringgammaglobulin

Clinical Trials (4)

Total enrollment: 84 patients across 4 trials

NCT00520494CSL BehringVivaglobin

Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency

Start: Mar 2007Est. completion: Oct 200818 patients
Phase 4Completed
NCT00542997CSL BehringHuman Normal Immunoglobulin for Subcutaneous Administration

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy

Start: Sep 2007Est. completion: Aug 200951 patients
Phase 3Completed
NCT00263237Allergy TherapeuticsSTA-5326

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

Start: Dec 2005Est. completion: Jul 200810 patients
Phase 1Completed
NCT00661401CSL Behringgammaglobulin

Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin

Start: Jan 2002Est. completion: Nov 20025 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.